Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
#3PRI RANKED
Most Cited Paper
in Acute Myeloid Leukemia Research
18 Months Post-Publication
Class of 2026
“Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
gilteritinib · FLT3 internal tandem duplication (FLT3-ITD) · Allogeneic hematopoietic stem cell transplantation (allo-HSCT) · post-transplant maintenance · FLT3 inhibitor · Measurable residual disease (MRD) · relapse-free survival · Overall survival · MRD-based therapy · First complete remission · AML
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026. Accessed 2026-07-31. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459